Occupational Skin Disease Among 923 Finnish Dental Nurses
Doctor’s Notes · Life in Motion · Evidence Review
Editorial disclosure: The featured scene is an AI-created illustration of a fictional work, home or research setting. It is not a patient, diagnosis, before-and-after image or Dr. Arsy #003 treatment result.
The question behind this paper
This review looks at dental gloves, latex, rubber chemicals and acrylates. The aim is to preserve the study’s actual population, denominator, design and timepoint so a useful signal does not become a universal claim.
Study snapshot
| Study element | Reported detail |
|---|---|
| Population | 923 eligible female dental nurses; 799 interviewed, 245 physician-reviewed, 133 selected and 107 clinically examined |
| Design | Staged occupational survey with clinical examination, prick testing and patch testing |
| Timepoint | Current and historical work-related dermatitis at evaluation |
| Key result | Twenty-two new occupational skin diseases were diagnosed among 107 examined. Across the study there were 29 allergic contact dermatitis, 15 contact urticaria, 12 irritant contact dermatitis and one onychomycosis case; 42% of cases were absent from the register. |
How to interpret the result
The changing denominators are the central reading skill. The study supports active case-finding in dental work, not a claim that every dental nurse faces the same probability.
Important limitation: Each stage used a more selected denominator, so examination yields cannot be applied to all 923 nurses. Exposures and glove materials may differ today.
Questionnaires, examinations, sensors, patch tests and administrative records answer different questions. A screening or monitoring result can guide the next step, but it does not diagnose the cause of one person’s rash. An association can identify a pattern worth investigating without proving that a single task, material or personal factor caused every event.
Questions a worker, family or clinician can ask next
- What exactly was measured: reported symptoms, visible signs, allergy, work loss or quality of life?
- Which denominator applies to the quoted percentage: everyone invited, respondents, symptomatic people, examined participants or a selectively tested subgroup?
- Did the study compare groups or follow change over time, and what factors could still explain the difference?
- Would clinician examination, occupational-health review or clinician-directed testing change the practical plan?
- What requires prompt medical evaluation, including rapidly spreading redness, drainage, fever, severe pain, breathing symptoms or major loss of function?
Primary and authoritative sources
- Primary medical research record: PubMed PMID 15128317
- Authoritative guidance relevant to this topic
- American Academy of Dermatology: eczema skin-care guidance
PubMed indexing is not NIH endorsement of a study’s interpretation, this article or any product.
Where a cosmetic moisturizer fits
Dr. Arsy #003 is a cosmetic moisturizer for hydration, moisture-barrier support and dry-skin comfort. This study did not test #003, and outside research does not become a product result. #003 is not an eczema medicine and this article makes no treatment, cure, prevention, pediatric-safety or 24-hour claim.
Bottom line
The responsible conclusion is narrow: keep the population, denominator, comparator, timepoint and limitations attached, then use the evidence to ask better clinical and exposure-control questions rather than promise a universal result.